Brad S. Kahl, MD, Washington University School of Medicine

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.

Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.

Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.

Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.

Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.

A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.